Olmesafe-AM 5 mg+20 mg (Tablet)
Unit Price: ৳ 12.00 (3 x 10: ৳ 360.00)
Strip Price: ৳ 120.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Amlodipine besilate olmesartan medoxomil |
| Company | Orion pharma ltd |
| Also available as |
Indications
- Treatment of hypertension alone or with other antihypertensive agents
- Lowering blood pressure
- Initial therapy for patients likely to need multiple antihypertensive agents
Pharmacology
- Amlodipine - dihydropyridine calcium channel blocker
- Inhibition of transmembrane influx of calcium ions into vascular smooth muscle
- Greater effect on vascular smooth muscle cells than on cardiac muscle cells
- Peripheral arterial vasodilator
- Olmesartan Medoxomil - blockage of vasoconstrictor and aldosterone-secreting effects of angiotensin II
- Selective blocking of the binding of angiotensin II to the AT1 receptor
Dosage & Administration
- Substitution of individually titrated components
- Initial therapy with 5/20 mg once daily for 1-2 weeks
- Titration up to a maximum of 10/40 mg once daily
- Recommended starting dose of Amlodipine is 2.5 mg in patients 75 years
- Combination drug not recommended in patients >75 years old
Interaction
- Attenuation of antihypertensive effect by NSAIDs including selective COX-2 inhibitors
- Close monitoring of blood pressure, renal function, and electrolytes
Contraindications
- Cannot be co-administered with Aliskiren in patients with diabetes
Side Effects
- Peripheral edema
- Headache
- Flushing
- Dizziness
- Sprue-like enteropathy
Pregnancy & Lactation
- Pregnancy Category D
- Avoid use in 2nd and 3rd trimester
- Potential adverse effects on the nursing infant
- Decision-making regarding nursing in consideration of drug importance to the mother
Precautions & Warnings
- Risk of hypotension in volume- or salt-depleted patients
- Risk of vasodilation in patients with severe aortic stenosis
- Risk of increased angina frequency, duration, or severity in patients with severe obstructive coronary artery disease
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No overall differences in safety or effectiveness between subjects 65 years of age or older and younger subjects
- No studies in patients with renal impairment
- Initial therapy not recommended in hepatically impaired patients
Overdose Effects
- No information available on overdose in humans
Therapeutic Class
- Combined antihypertensive preparations
Storage Conditions
- Do not store above 30°C
- Keep away from light
- Keep out of the reach of children